Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Aminophylline on the Levels of Neutrophil Gelatinase-Associated Lipocalin (Ngal) in Asphyxiated Term Neonates Publisher Pubmed



Malekisadeghi N1 ; Rahmani P2 ; Aghsaeifard Z3, 4 ; Heidari G1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pediatrics, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
  2. 2. Pediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Internal Medicine, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Archives of Physiology and Biochemistry Published:2022


Abstract

Objective: Our study evaluates the effects of aminophylline in the reduction of NGAL levels in perinatal asphyxia. Methods: Term neonates with hypoxic ischaemic encephalopathy who were divided into two groups, the treatment and placebo. Urine NGAL levels were measured on day one and four of the treatment using BIOPORTO kits in both the groups. Results: Day 1 NGAL levels were not statistically different in either group irrespective of the age, gender and the mode of delivery. on 4th day, NGAL in treatment group significantly decreased as compared to day 1 levels and placebo day-4 levels. significant differences were seen between first and fourth day NGAL levels among children with normal and caesarean birth and among female and male neonates. Conclusions: Following the treatment with aminophylline, NGAL levels in asphyxiated neonates are likely to reduce. Further studies based on other kidney dysfunction parameters can lead to the better and accurate conclusions. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
10. Complications in Patients With Cardiac Penetrating Trauma, Cardiovascular and Hematological Disorders - Drug Targets (2021)
11. Clinical Post-Transplant Lymphoproliferative Disorders, Cardiovascular and Hematological Disorders - Drug Targets (2022)